Abstract: The invention provides compounds of the formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.

Abstract: An SGLT2 inhibiting compound is provided having the formula A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

Abstract: Novel compounds are provided which are inhibitors of MTP and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and have the structure including pharmaceutically acceptable salts thereof or prodrug esters thereof, wherein q is 0, 1 or 2; Rx is H, alkyl, aryl or halogen; A is (1) a bond; (2) —O—; or (3) B is: and wherein L2, L1, R1, R2, R3, R3′, R3a, R3b, R4, R4′, R5, X,  are as defined herein.

Abstract: Lactam derivatives of the formula where X is —C(═O)NR3′—, —NR3′C(═O)—, —C(═NCN)NR3′—, —NR3′C(═NCN)—, —CH2NR3′—, —CH(alkyl)NR3′—, —CH(COOalkyl)NR3′—, —CH(CH2OH)NR3′—, —C(CH2Oalkyl)—; R1 is halo, alkyl, cycloalkyl, alkyl(cycloalkyl), aryl, (aryl)alkyl, (aryl)alkenyl, (aryl)alkynyl, O-alkyl, O-alkenyl, O-aryl, O-alky(aryl), O-alkyl(heterocyclo), COO-alkyl, C)-alkyl, CO-amino, CO-substituted amino, alkyl-CO-amino, alkyl-CO-substituted amino, NHCO-alkyl, NHCO-aryl, NHCO-alkyl(aryl), NHCO-alkyl(heterocyclo), N(alkyl)CO-alkyl, N(alkyl)CO-aryl, N(alkyl)CO-heterocyclo, N(alkyl)CO-alkyl(aryl), N(alkyl)CO-alkyl(heterocyclo); R2 is hydrogen, alkyl, halo, aryl, (aryl)alkyl, O-alkyl, amino, substituted amino; R3 and R3′ are the same or different and are independently selected from hydrogen, alkyl or alkyl(aryl); R4 which

Abstract: Small particle size catalysts having an average particle size of less than 20 or 10 microns, which agglomerate when contacted with a hydrocarbon liquid, are easily dispersed in the hydrocarbon liquid by first forming a mixture comprising the catalyst particles and one or more non-acidic, liquid polar oxygenates, such as an alcohol, ketone, ester, ether or mixture thereof. The mixture is contacted with the hydrocarbon liquid in which the particles then readily disperse. This process is useful for adding fresh or regenerated small particle size catalyst to catalytic hydroprocessing process slurries, including a reactive Fischer-Tropsch hydrocarbon synthesis slurry. One to four carbon atom alcohols are preferred oxygenates for use with a Fischer-Tropsch slurry.

Abstract: Partially deactivated catalyst in a slurry hydrocarbon synthesis process is rejuvenated employing a cyclic rejuvenation process in which syngas or CO flow into the slurry is stopped to stop the hydrocarbon synthesis reaction, the CO purged out of the slurry with a purge gas in the presence of hydrogen, the catalyst rejuvenated with a hydrogen containing rejuvenating gas and the hydrocarbon synthesis reaction restarted by passing the synthesis gas feed back into the reactor. All or a portion of the purge gas and/or the rejuvenating gas may be recycled during the respective purge and/or rejuvenation. The hydrogen required during the purge is typically part of the purge gas.